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Leishmania infantum infection including treatment and follow up in domestic animals other than 
dogs and cats has not been described at this moment. This article describes the anti-Leishmania 
treatment and follow-up of a ferret (Mustela putorius furo) with leishmaniosis. A combined 
therapeutic protocol established for the patient, not yet approved for ferrets, was a combination 
of meglumine antimoniate plus allopurinol. A follow-up was established monthly during the first 
year in order to monitor the health condition of the patient. Six months after commencing 
allopurinol therapy, xanthine crystalluria was observed in urine sediment with no other urine 
alterations detected by urine analysis. The ferret worsened progressively with diarrhoea and 
weight loss after cohabiting with another ferret diagnosed with cryptosporidiosis. 
Cryptosporidium parvum was isolated in faecal samples from the patient detected by three 
different methods including Ziehl-Neelsen staining, a qualitative test to detection of C. parvum 
antigens and finally a specific molecular analysis to characterize the species. To the best of the 
authors  ́knowledge, this is the first report providing information about anti-Leishmania protocol 
therapy used and follow-up in a domestic ferret with clinical leishmaniosis. Veterinarians 
practicing in endemic areas should be aware of this infection in ferrets at risk and their 
susceptibility especially when immunosuppressive conditions are present. 
Keywords: Cryptosporidium parvum; ferret; Leishmania infantum; PCR; serology; treatment.  
 
1. Introduction 
Zoonotic leishmaniosis due to Leishmania infantum is a vector-borne disease endemic in 
Southern Europe, Asia, North Africa and South America. Dogs are the main reservoir for this 
infection and the disease can be fatal some circumstances if not treated in people and dogs 
(Solano-Gallego et al., 2011). It has been estimated, based on seroprevalence studies from Italy, 
Spain, France and Portugal, that 2.5 million dogs in these countries are infected by L. infantum 










leishmaniosis are mainly caused by the same zymodeme MON-1 (Baneth et al., 2008). In areas 
where L. infantum is transmitted to dogs, other animals such as cats, and other non-conventional 
household pets are likely to be in contact with the parasite and can also be potentially infected 
(Pennisi, 2015), although with lesser impact in comparison to the role of the dog in the 
epidemiology of this infection. It has been suggested that cats may act as a peridomestic reservoir 
and not only as accidental hosts (Solano-Gallego et al., 2007). In the same way, wild mammals 
have been considered as potential silent reservoirs of L. infantum in the Mediterranean area, 
suggesting the presence of chronic subclinical infection without evidence of clinical signs and 
they may contribute to maintaining the zoonotic cycle in an area where the presence of the dog is 
limited (Alcover et al., 2020). However, one of the common problems in the identification of 
alternative reservoirs is the lack of reagents to detect the infection, furthermore specific 
techniques such as xenodiagnosis is not always possible to be applied.  
In endemic areas with high canine leishmaniosis prevalence, the detection of the 
Leishmania infection in other household pets like cats has been described, although information 
concerning the epidemiology and clinical picture is scarce. Moreover, the proportion of infected 
cats is inferior in comparison to dogs in the same endemic area. Immunosuppressive conditions 
in this species have been involved with promoting factors to increase the susceptibility to develop 
clinical disease (Solano-Gallego et al., 2011; Pennisi and Persichetti, 2018). 
Allopurinol and meglumine antimoniate are the two main drugs used for the treatment of 
L. infantum in dogs (Solano-Gallego et al., 2011) and cats (Pennisi et al., 2015). Nevertheless, the 
use of these two drugs is off-label and there is no information in cats being empirically evidence-
based (Pennisi and Persichetti, 2018).  
The domestic ferret (Mustela putorius furo) is a small mustelid considered to be the same 
species as the European polecat and was domesticated between 2000-3000 years ago (Talbot et 
al., 2013). The present report, which describes therapeutically findings observed in a domestic 
ferret with leishmaniosis along with follow-up data thus provides information on the disease in 










since about the 1970 ś across Europe and the United States of America (Shepherd, 2006; Talbot 
et al., 2013), with an official registered population of 20.000 pet-ferrets in Spain (Ministerio de 
Agricultura, Alimentación y Medio Ambiente, Spanish Government, 2015),  which could be 
considered potential natural host for Leishmania. 
 
2. Methods 
A 4-year-old intact female ferret from Valencia (39° 28' 12.864''N, 0° 22' 36.48''W), on 
the east coast of Iberian Peninsula, was clinically evaluated in February 2019 because of a 
presence of a nonpruritic dermal lesion in right pinna. This ferret was adopted at the age of two 
years with unknown previous history. The patient lives in an apartment with other ferrets and has 
outdoor terrace access. The owner provides the pet-ferret an environmental enrichment with 
mental stimulation and outlets for its activity needs and an indoor housing appropriate for agile 
active, ferrets with climbing levels and multiple sleeping areas. Furthermore, ferret care is supply 
with a highly digestible diet consisting of a high-quality animal protein and fat, with minimal 
carbohydrate and fiber commercial ferret diet. It was under chronic medical management with 
prednisolone 0,5 mg/kg Per os (PO), twice a day (BID), and cyclosporine 7 mg/kg, PO once a 
day (SID) because of inflammatory bowel disease diagnosed one year earlier and also it was 
diagnosed a suppurative cholangitis six months prior to presentation.  
On physical examination, the ferret presented an erythematous and edematous papular 
painless lesion with a diameter of 5 mm in the right ear pinna (Figure 1a) with no other apparent 
clinical signs.  
A skin lesion sample was taken by fine needle aspiration and stained with Diff-Quick 
stain for cytological examination. Cytology results revealed pyogranulomatous inflammation in 
which infectious agents were not visualized. Topical therapy with was iniciated with 
marbofloxacin 3 mg/clotrimazole 10 mg/dexamethasone plus 0.9 mg per ml suspension 










(Marbocyl® 5mg, Vetoquinol, France) 2 mg/kg PO BID during 3 weeks (Figure 1b, 1c). A 
follow-up exam three weeks later revealed little improvement of the dermatitis. 
A full thickness biopsy of the lesion was taken under short general anesthesia. The lesion 
was completely excised, fixed in 10% neutral-buffered formalin, and submitted for histological 
examination. A severe chronic diffuse pyogranulomatous dermatitis with proteinaceous edema, 
serocellular crusts, and intramacrophagic oval organisms with eccentrical nuclei and pale 
cytoplasm, approximately 3 to 4 μm in size, interpreted as protozoas (Leishmania spp.) or fungal 
organisms (Histoplasma spp.), was observed microscopically (Figure 2).  
Anti-Leishmania treatment was not initiated because lesion was completely excised and 
any anti-Leishmania therapeutic protocol for ferrets was available or documented in that moment. 
Immune-modulating drugs dosage were reduced to avoid possible drug immunosuppression 
(prednisolone 0.5 mg/kg PO SID and cyclosporine 7 mg/kg PO SID) and oral nutritional 
supplements based on S-adenosyl methionine 31.25 mg, silybin 3.75 mg and vitamin E 1.5 mg 
(Hepatosil Plus®, Opko health, Spain) SID were added to the treatment (Figure 1d, 3a, 3b). 
During follow-up, four weeks later, a new papular dermatitis was detected on cicatricial edge 
from previous surgical incision on the right ear pinna (Figure 3c). A sample from the cutaneous 
lesion was taken by needle aspiration for parasite culture in Novy-MCNeal-Nicolle medium 
(NNN), which tested positive for Leishmania parasites (Figure 3d). Additional diagnostic 
procedures included detection of parasite DNA by PCR from peripheral blood sample and 
Whatman filter paper number 3 with aspirated material from the perilesional excised area, 
immunohistochemistry specific against L. infantum and anti-Leishmania antibodies detected by 
western blot, immunofluorescence indirect test and enzyme-linked immunosorbent assay (Giner 
et al., 2020). Delayed type hypersensitivity (DTH) reaction to leishmanin was evaluated using an 
inactivated suspension of 3×108 L. infantum promastigotes (MHOM/FR/78/LEM75) per ml in 
0.2% phenol-saline, with a protein content of 30 µg/ml. The solution (100µl) was intradermally 
injected in the skin of the groin. Skin reactions were recorded after 72 hours and an induration or 










An anti-Leishmania therapeutic protocol was established with allopurinol at 10 mg/kg 
BID PO sine die (Zyloric® 100 mg, Faes Farma, Spain) and meglumine antimoniate 
(Antishmania®, Fatro, Italy) during three weeks at increasing doses every week to control 
possible drug adverse effects from 25 mg/kg BID the first week to 50 mg/kg BID the third week 
subcutaneously (Figure 4a and 4b). Anticoagulated blood sample was analysed by an automated 
haematology analyser (LaserCyte Idexx, Westbrook, USA) to perform a complete cells blood 
count. Clinical biochemistry was analysed with an automatic analyser (Catalyst One Idexx, 
Westbrook, USA) including the following parameters: alanine amino-transferase (ALT), alkaline 
phosphatase (ALKP), serum gamma glutamyl transferase (GGT), total bilirubin (TBil), total 
cholesterol (CHO), glucose (GLU), total protein concentrations (TP), creatinine (CRE), blood 
urea nitrogen (BUN), calcium (Ca), inorganic phosphorus (P). Urine analysis was performed 
including urine specific gravity (USG) and urine protein to creatinine ratio (UPC). Serum protein 
electrophoresis was run manually with agarose gels (Sebia, Evry, France) and densitometer 
(Shimadzu CS-9000, Kyoto, Japan) was used for scanning the electrophoretograms.  
Cryptosporidium infection was detected by faecal smear by modified Ziehl-Neelsen 
staining method according to World Organization for Animal Health (OIE) (OIE, 2018). Later, a 
rapid immunochromatographic test for the qualitative detection of Cryptosporidium spp. antigens 
in faeces (FASTest® CRYPTO Strip, MEGACOR Diagnostik GmbH, Hörbranz, Austria) was 
used to confirm the diagnosis. Finally, molecular analysis was performed to characterize and 
determine the species of Cryptosporidium parasite. For this purpose, total genomic DNA was 
extracted from 180 – 200 mg of stool samples from the ferret using a QIAamp® Fast DNA Stool 
Mini Kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions. Purified DNA 
was stored at 4°C until used in polymerase chain reaction (PCR). Real-time PCR amplification 
specific for Cryptosporidium parvum DNA was performed according to Jothikumar et al. (2008). 












 A follow-up visit one month since the treatment was initiated demonstrated clinical 
response and it was observed that the ear pinna lesions had almost disappeared (Figure 4c). At 
any rate, a new sample was taken by needle aspiration for parasite culture in NNN which was 
again positive for Leishmania promastigotes. The same biochemical abnormalities were observed 
as initially with persistent alteration of protein electrophoresis with hypergammaglobulinemia 
and elevated serum enzyme activities (ALT, ALKP and GGT). 
Because the anti-Leishmania protocol therapy was tolerated well with no renal 
compromise or clinically apparent side effects noted, treatment with allopurinol at 10 mg/kg BID 
PO sine die and meglumine antimoniate at 50 mg/kg BID was continued. Three weeks following 
completion of the treatment, blood PCR was negative for L. infantum and new sample for parasite 
culture in NNN was taken by needle aspiration from affected area which was negative for 
Leishmania parasites. Equally, on this follow-up the ferret was appeared healthy and 
haematological and biochemical tests were repeated observing a partial resolution of the alteration 
in protein ś electrophoresis (Tables 1 and 2). For these reasons, meglumine antimoniate treatment 
was discontinued after 56 days. The ferret continued to be treated with allopurinol at the same 
dose for five months. Follow-up visits (Figure 4d) to the attending veterinarian were made every 
month monitoring clinicopathological parameters including complete blood count (CBC), 
biochemistry, urine analysis, anti-Leishmania antibody levels by serology and PCR (Table 3). On 
a follow-up visit six months since treatment was initiated, xanthinuria was observed in urine 
sediment and no other urine alterations were detected by urine analysis (Figure 5). The presence 
of xanthine crystals was associated to the allopurinol treatment. Abdominal ultrasound before 
starting allopurinol was performed and no urinary tract alterations were observed. 
Because serology and protein electrophoresis (Figure 6) revealed an improvement of the 
animal status, allopurinol therapy was discontinued temporarily to prevent xanthine urolithiasis. 
Xanthine crystals were not persisted after withdrawal of allopurinol two weeks later observed by 
urine analysis. Response to treatment after withdrawal of allopurinol was considered as effective 










Seven months after leishmaniosis diagnosis was made, the ferret was examined because 
of severe weight loss, apathy, diarrhoea and dyspnoea with tachypnea. The ferret ś owner reported 
that the patient lived with two new ferrets diagnosed with cryptosporidiosis. A blood sample was 
collected and submitted for follow-up CBC and serum biochemical profile. The CBC showed 
neutrophilia and marked monocytosis. Serum biochemical profile revealed increases in ALT, 
GGT, ALKP activities, and TBil (10.3 mg/dl) concentration Table 1, November 2019). Equally, 
hyperproteinemia and alteration of electrophoresis with hypergammaglobulinemia and a reduced 
albumin/globulin ratio was detected. Thoracic radiographs revealed a diffuse broncointerstitial 
pattern with alveolar infiltrates compatible with a pulmonary parenchyma disorder such an 
infectious pneumonia (bacterial, fungal, viral protozoal or parasitic in origin) or neoplasia. 
Cryptosporidium infection was detected by faecal smear stained by modified Ziehl-Neelsen, a 
rapid immunochromatographic test for the qualitative detection of Cryptosporidium spp. antigens 
in faeces (Figure 7) and a positive result obtained in molecular analysis. Immunocompromised 
hosts are more likely to develop clinical signs of cryptosporidiosis (Scorza and Tangtrongsup, 
2010; Kumar et al., 2016). Therefore, immune-modulating drugs were discontinued because they 
were considered a possible cause of immunosuppression in this patient. DTH reaction to 
leishmanin was negative and no induration or eritematous area was observed. Azithromycin 
(EFG, Cinfa, Spain) was administered at 10 mg/kg PO once a day for one month. Because 
immunosuppressive status is one of the strongest risk factors for overt clinical disease and 
serology in the patient still remained positive, allopurinol 5 mg/kg PO BID sine die was added to 
the therapy. Respiratory constants and stools were normal within a week of initiating therapy. 
Currently, the animaĺ s general clinical status is stable and the ferret continues with the same oral 












The present study represents the first report describing leishmaniosis treatment and one-
year follow-up with routine physical examination, laboratory tests, serology and PCR in a 
domestic ferret (Mustela putorius furo) with a well-maintained quality of life. 
Parasitic virulence, nutritional status, age, the host genetic and response factors in canine 
leishmaniosis are known to contribute to the disease although the progression of the disease after 
primary infection is only partly understood. Infection in dogs may be subclinical or manifested as 
a self-limiting disease, or a severe, and sometimes, fatal illness (Solano-Gallego et al., 2009). 
Subclinical infection is not necessarily permanent and factors such as immunosuppression or 
concomitant diseases lead to the progression of clinical disease in dogs (Solano-Gallego et al., 
2011) as in cats (Pennisi and Persichetti, 2018). Leishmaniosis has been associated in cats with 
an impaired immunocompetence due to several factors, including retroviral infections, 
immunosuppressive treatments and concomitant debilitating diseases, thus suggesting that these 
conditions may act as promoting factors (Pennisi and Persichetti, 2018; Fernández-Gallego et al., 
2020). In humans, whereas most immunocompetent individuals will not develop disease after 
Leishmania infection, immunosuppression is a well-established risk factor for the development 
of the disease, as in patients with human immunodeficiency virus (HIV) mainly and a wide range 
of non-HIV-related immunosuppressive states falling under the realm of transplantation 
medicine, rheumatology, hematology, and oncology medicine (Van Griensven et al., 2014). 
Immunosuppression induced by immunomodulating drugs such cyclosporine in dogs 
with atopic dermatitis have been described (Navarro et al., 2008). Although ferrets often are 
relatively resistant to the immunosuppressive effects of prednisolone (Chen, 2008; Chen, 2010), 
this clinical case reports a ferret with a suggested immunosuppression condition initially 
associated with immune-modulating drugs therapy (prednisolone and cyclosporine). 
Furthermore, Leishmania infection probably could increase the immunosuppression status of the 
patient because an intestinal cryptosporidiosis and supposed pulmonary cryptosporidiosis was 
detected seven months since Leishmania infection was diagnosed. Cryptosporidium spp. are 










self-limiting and subclinical (Patterson and Fox, 2007; Powers, 2009). Cryptosporidium 
infections of the ileum are the most common, although gastric, respiratory, and conjunctival 
infections have been reported in immunosuppressed people (Scorza and Tangtrongsup, 2010).  
According to a recent feline retrospective leishmaniosis study, median survival time in a 
group of cats treated specifically for leishmaniosis without concomitant diseases was longer than 
in another group with concomitant diseases or known immunosuppression status; however, no 
statistical differences were seen between groups (Fernández-Gallego et al., 2020).  
A negative result in DTH test is observed in acute cases of visceral leishmaniasis in 
humans (Sundar and Rai, 2002) and dog with clinical leishmaniosis (Solano-Gallego et al., 2005), 
whilst, a positive result can be detected in human cases where kala-azar has been cured (Sundar 
and Rai, 2002) and in dogs that improve after anti-Leishmania treatment (Solano-Gallego et al., 
2001). In this ferret, a negative result detected by DTH could be interpreted as potentially no 
resistant to Leishmania infection. 
Laboratory findings revealed high serum enzymes activities (ALT, ALKP, GGT) on each 
follow up serum chemistry evaluation performed. Various hepatic diseases have been reported in 
ferrets; the most common liver disorders encountered in this species are inflammatory, infectious 
and toxic hepatic diseases; and less commonly hepatic lipidosis, and hepatic neoplasia. Owing to 
most previously mentioned liver diseases remained often subclinical may lead to difficulties in 
diagnosing those conditions accurately (Huynh et al., 2013). Hepatobiliary failure due to L. 
infantum has been documented in dogs experimentally as well as in natural infection, recording 
laboratory alterations associated with liver injury and histopathological changes in the liver which 
are characterized by the presence of a mononuclear inflammatory cell infiltration (Valladares et 
al., 1997; Rallis et al., 2005; Moreira et al., 2016). Bile culture was performed in the ferret of this 
report with negative results and abdominal ultrasound did not revealed biliary tree or liver 
parenchyma abnormalities. The cause of ALT, ALKP and GGT elevations in the ferret, and if 











Anti-Leishmania treatment selection between meglumine antimoniate versus miltefosine 
was based on the better clinical efficacy of meglumine antimoniate in long term clinical setting 
in dogs (Manna et al., 2014). Different treatment protocols with variable survival time have been 
described in cats with clinical leishmaniosis: allopurinol alone, a combination meglumine 
antimoniate plus allopurinol, a combination miltefosine plus allopurinol, and finally meglumine 
antimoniate alone with very variable survival time between anti-Leishmania treatments 
(Fernández-Gallego et al., 2020). 
Although combined therapeutic protocol based on allopurinol and meglumine 
antimoniate was well tolerated in this patient, information is lacking on pharmacokinetic and 
pharmacodynamic characteristics of these drugs in ferrets and also about their safety. Clinical 
improvement was observed in this ferret and papular dermatitis was resolved within a few weeks 
after treatment was initiated. In the same way, protein electrophoresis alterations were partially 
resolved until Cryptosporidium infection was detected in roughly seven months since anti-
Leishmania treatment was initiated. The prolongation of the anti-Leishmania combined treatment 
by 2-3 weeks has been described in dogs and may be considered if patient improvement is 
inadequate (Solano-Gallego et al., 2011). In our patient, the clinical decision to increase the anti-
Leishmania combined treatment for four more weeks was based on positive results in parasite 
culture of a new material aspirated from the previous lesion site.  
However, xanthinuria was observed in urine sediment during a follow-up six months after 
long-term administration of allopurinol. Presence of xanthine crystals is a result of the inhibit ion 
of a specific enzyme, xanthine oxidase, which is part pathway of purine degradation and usually 
occurs secondary to therapy with allopurinol influenced by several variables including the dosage 
of allopurinol, quantify of dietary purine precursors, the rate of degradation and hepatic function. 
Our findings suggest that the presence of xanthinuria can be found during allopurinol therapy in 
ferrets. Treatment of leishmaniosis in this ferret was not based on scientific evidence reports. At 











This report demonstrates that meglumine antimoniate plus allopurinol seems to be 
effective as anti-Leishmania treatment in a ferret with clinical leishmaniosis. In general, close 
clinical and analytical monitoring should be performed to detect drugs side effects such as 
xanthinuria associate with allopurinol administration. Veterinarians practicing in endemic areas 
should be aware of this infection in ferrets at risk and their susceptibility especially when 
immunosuppressive conditions are present. 
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Figure 1: Right ear pinna from the affected ferret with dermatological lesion associate to L. 
infantum. a Edematous papular lesion 5 mm in diameter before the lesion was excised. b Right 
ear pinna after full thickness biopsy for histopathological evaluation. c Cicatricial edge 10 days 
after lesion was excised. d Papular dermatitis detected on cicatricial edge from previous surgery 
during a follow-up one-month after surgical incision (lateral view).  
Figure 2: Timeline of the treatment periods and following up visits. 
Figure 3: Clinical lesion detected in the ferret before anti-Leishmania treatment was initiated. a-
b Clinical sign observed at the relapse; medial view (a) and dorsal view (b). c Fine needle 
aspiration from papular lesion for parasite culture. d Leishmania promastigotes forming in 
rossetes from parasite culture in NNN medium. Giemsa stain (40x). 
Figure 4: Dermatological clinical sign improvement during anti-Leishmania treatment. a-b 
Different right ear pinna views on a follow-up visit one month after the initiation of treatment 
showing clinical response. c Fine needle aspiration from affected area for a new parasite culture 
in NNN medium. d Ear pinna four months since anti-Leishmania therapy was initiated. 
Figure 5: A photomicrograph of urine sediment xanthine crystals. Unstained sediment, x40 
objective. 
Figure 6: Agarose gel electrophoretograms of serum proteins of the ferret before starting anti-
Leishmania treatment (a) and during the follow up (b, c, d, e, f, g, h). b One-month follow-up 
(June 2019). c Two-month follow-up (July 2019). d Three-month follow-up (August 2019). e 
Four-month follow-up (September 2019). f Five-month follow-up (October 2019). g Six-month 
follow-up (November 2019). h Eight-month follow-up (January 2020). 
Figure 7: a Oocysts of Cryptosporidium spp. Ziehl Neelsen, 40×. b Qualitative detection of 
Cryptosporidium antigens by a rapid test-kit. A red test line indicates a positive result whilst a 




















Table 1. Body weight, haematological and biochemical parameters determined in the 
leishmaniotic ferret at the first veterinary examination before treatment (March 2019) 

























Body weight (g) 625 635 665 620 640 530 505 520 500 420 
Haematology           
WBC (K/μL) 4.46 5.56 5.34 4.97 4.91 5.88 3.57 5.99 6.25 nd 
Neutrophils 
(K/μL) 
3.35 3.41 3.80 3.54 2.61 4.91 2.37 4.48 4.55 nd 
Lymphocytes 
(K/μL) 
0.37 1.16 0.32 0.34 1.37 0.17 0.41 0.36 0.53 nd 
Monocites (K/μL) 0.61 0.83 0.95 0.89 0.79 0.51 0.66 0.90 0.92 nd 
Eosinophils 
(K/μL) 
0.11 0.12 0.22 0.12 0.11 0.21 0.08 0.16 0.25 nd 
Basophils (K/μL) 0.02 0.05 0.05 0.07 0.03 0.08 0.05 0.09 0.01 nd 
RBC (M/μL) 9.89 8.17 9.28 11.43 8.82 8.57 8.42 7.59 9.27 nd 
Haematocrit (%) 47.6 44,1 43.2 59.9 47.2 57.0 45.3 43.5 49.9 nd 
Haemoglobin 
(g/dL) 
13.9 14.3 14.7 15.2 15.2 12.4 15.6 16.0 18.9 nd 
MCV (fL) 48.1 54.0 46.5 52.4 53.5 66.5 53.8 57.3 53.8 nd 
MCH (pg) 14.1 17.5 15.9 13.3 17.2 14.5 18.5 21.1 20.4 nd 
MCHC (g/dL) 29.3 32.5 34.1 25.4 32.1 31.8 34.4 36.7 38.0 nd 
RDW (%) 17.0 16.9 18.1 17.7 16.6 17.5 17.1 16.4 16.8 nd 
Platelets (K/μL) 357 327 278 230 207 102 271 171 309 nd 
Blood Chemistry           
ALT (U/L) >1000 >1000 634 >1000 657 370 >1000 >1000 >1000 nd 
ALKP (U/L) 239 255 193 154 169 194 389 538 649 nd 
GGT (U/L) 250 205 216 137 119 436 735 876 752 nd 












369 379 377 321 228 296 365 360 362 nd 
Glu (mg/dL) 131 152 107 113 119 126 102 100 155 nd 
Crea (mg/dL) 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.4 nd 
BUN (mg/dL) 21 20 34 19 32 31 28 19 34 nd 
P (mg/dL) 5.8 7.7 7.0 5.9 5.6 7.5 6.7 7.0 7.8 nd 
Ca (mg/dL) 9.4 9.7 9.3 9.2 8.2 8.4 8.9 8.7 8.8 nd 
Abbreviations: WBC White Blood Count, RBC Red Blood Count, MCV mean corpuscular volume, 
MCH mean corpuscular hemoglobin, MCHC mean corpuscular haemoglobin concentration, 














Table 2. Electrophoretograms of serum proteins and urine analysis determined in the 
leishmaniotic ferret at the first veterinary examination before treatment (March 2019) 


























of serum proteins 
          
Total protein (g/dl) 8.7 10.5 9.7 7.9 7.8 7.0 8.4 8.9 7.4 nd 
Albumin (g/dl) 3.54 3.78 3.43 2.91 2.53 2.26 3.21 3.10 2.79 nd 
Total globulins (g/dl) 5.16 6.72 6.27 4.99 5.27 4.74 5.19 5.80 4.60 nd 
Alpha 1 globulins 
(g/dl) 
0.22 0.24 0.74 0.21 0.18 0.14 0.19 0.40 0.93 nd 
Alpha 2 globulins 
(g/dl) 
1.11 0.75 0.55 0.75 0.97 0.56 1.19 1.00 0.44 nd 
Beta globulins (g/dl) 1.63 1.26 0.75 0.91 2.71 1.23 1.70 2.30 1.27 nd 
Gamma globulins 
(g/dl) 
2.20 4.47 4.23 3.12 3.24 2.81 2.11 2.10 1.96 nd 
A/G 0.69 0.56 0.55 0.58 0.48 0.48 0.62 0.53 0.61 nd 
Urine analysis           
UPC nd nd nd nd nd nd 0.21 nd nd 0.35 
USG 1.029 1.028 1.029 1.035 1.035 1.030 1.028 1.035 1.032 1.030 
Sediment - - - - - - - - - Xanthine 
crystals 
Abbreviations: A/G albumin:globulin ratio, UPC urine protein to creatinine ratio, USG urine 
specific gravity, nd not determined, - negative. 













Table 3 Results of Leishmania infection confirmation tests recorded during the follow-
up. 
 
















Cytology - nd nd nd nd nd nd 
H&E  + nd nd nd nd nd nd 
IHQ nd + nd nd nd nd nd 
Culture nd + nd + - - nd 
Molecular 
(qPCR) 
Peripheral blood nd + - - - - - 
Paraffin block nd + nd nd nd nd nd 
Whatman filter paper 
from the skin lesion 












+ (0.684) + (0.619) 
IFAT(titer) Cut-off: 
1:20 







































nd nd nd nd nd nd nd 
Abbreviations: DTH delayed type hypersensitivity,H&E hematoxylin and eosin staining, IFAT 
immunofluorescence antibody test, IHQ specific immunohistochemistry for Leishmania 
detection, kDa kilodaltons, ELISA enzyme-linked immunosorbent assay, WB western blot, + 
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 Meglumine antimoniate plus allopurinol seems to be effective as treatment. 
 Xanthinuria associated with allopurinol therapy is a problem in ferrets. 
 Serology could be used as biomarkers for monitoring response to treatment. 
 L. infantum and C. parvum co-infection could alter the ferret immune response. 
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